BEAM Q3 2022 Earnings — Beam Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

BEAMBeam Therapeutics Inc.

$3B

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$16M+1970.6% YoY

Gross Profit

-$69M-439.8% margin

Operating Income

-$91M-577.9% margin

Net Income

-$110M-693.6% margin

EPS (Diluted)

$-1.56

QoQ Revenue Growth

-5.1%

Cash Flow

Operating Cash Flow

-$74M

Free Cash Flow

-$86M

Stock-Based Comp.

$22M

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$636M

Stockholders' Equity

$714M

Cash & Equivalents

$157M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$16M	$763,000	+1970.6%
Gross Profit	-$69M	-$54M	-29.0%
Operating Income	-$91M	-$70M	-31.1%
Net Income	-$110M	-$28M	-289.7%